Polycystic kidney Disease Market, By Type (Autosomal Dominant Polycystic Kidney ease, Autosomal Recessive Polycystic Kidney Disease, Others), By Treatment (Medication, Surgery, Others), By Route of Administration (Oral, Parenteral, Others), By End-Users (Hospitals, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI476421 | Publish Date: May 2024 | No. of Pages: 170

Global Polycystic Kidney Disease Market Overview

Polycystic Kidney Disease Market accounted for US$ 97.142 million in 2020 and is estimated to be US$ 199.76 million by 2030 and is anticipated to register a CAGR of 7.50%.

Polycystic kidney disease is an inherited kidney ailment in which cysts and clusters form in the kidney, resulting in an enlarged kidney and gradual loss of kidney function. The cysts are spherical sacs that collect fluid and are noncancerous. The kidney suffers substantial damage as the number and size of cysts grows. Polycystic kidney disease can also lead to the development of cysts in the liver or elsewhere in the body. Other major complications of the condition include hypertension, kidney failure, a brain aneurysm, and persistent pain. Blood in the urine, kidney stones, urinary tract or kidney infections, and back or side pain are some of the other symptoms. Polycystic kidney disease (PKD) is a hereditary illness in which your kidneys develop multiple fluid-filled cysts. PKD cysts can affect the shape of your kidneys, including making them considerably larger, unlike the normally harmless simple kidney cysts that might form later in life. PKD is a type of chronic kidney disease (CKD) that causes kidney function to deteriorate and can eventually result in renal failure. Other consequences or difficulties associated with PKD include high blood pressure, liver cysts, and blood vessel abnormalities in the brain and heart. 

Global Polycystic Kidney Disease Market Dynamics

Growing case of kidney failure

The polycystic kidney disease market is driven by an increase in occurrences of renal failure or dialysis. Polycystic kidney disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people on dialysis, all of which will raise the polycystic kidney disease market. However, the polycystic kidney disease market will benefit from an increase in the frequency of kidney illnesses and advancements in the diagnosis and treatment of polycystic kidney disease. Furthermore, the polycystic kidney disease market may be hampered by a lack of awareness in poorer nations and the disease's last signs.

Increasing special regulatory designations

One of the major factors driving the polycystic kidney disease medicines market is the increasing special regulatory designations. Clinical research tests to assess the efficacy and safety of medications are funded by the orphan products grants programme (OPGP). For a limited time, organizations such as the US FDA and the European Medicines Agency (EMA) grant firms market exclusivity for pharmaceuticals they make. Tax credits for clinical trials and protocol support are also available to these pharmaceutical companies. Fast track and orphan drug designations are also given to some curative medications. During the market exclusivity period, generics are prohibited from entering the market, protecting orphan medicine sales. These variables make it easier for vendors to introduce pharmaceuticals, which helps them generate income. One of the important factors that will contribute to the expansion of the polycystic kidney disease medicines market is the increasing availability of attractive reimbursement policies. Individuals with polycystic kidney disease are the most common recipients of off-label medications. Despite the fact that an unique medicine for the treatment of the ailment was licensed in 2018, the high cost of the drug makes it difficult for patients to afford it. As a result, government and non-government groups have begun to implement reimbursement schemes to assist patients in receiving the care they require for a variety of renal disorders. These policies encourage suppliers to invest more in R&D in order to release better curative pharmaceuticals.

Global Polycystic Kidney Disease Market Segmentation

Polycystic Kidney Disease Market is segmented based on type, treatment, Route of Administration end-users, distribution channel and region.

On the basis of Type, the Polycystic Kidney Disease Market is segmented into Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others. Based on Treatment, the target market is segmented into Medication, Surgery, Others. Based on Route of Administration, the target market is segmented into Oral, Parenteral and Others. Based on End-User, the target market is segmented into Hospitals, Specialty Clinics and Others. Based on Distribution Channel, the target market is segmented into Hospital Pharmacy, Retail Pharmacy, Others.

Regional Insights:

On region the Polycystic Kidney Disease Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating the market during the forecast period because of advances in technology for kidney illnesses and increased efforts by pharmaceutical companies to develop novel formulations. Due to an increase in kidney problems and procedures, Europe is the second largest market for polycystic kidney disease. Due to increased measures taken by the government and pharmaceutical organisations to disseminate awareness and the existence of generic manufacturers, Asia-Pacific is likely to account for the biggest market share in the polycystic kidney disease market in the future years.

Polycystic Kidney Disease Market Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Type- Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others

By Treatment– Medication, Surgery, Others

By Route of Administration- Oral, Parenteral and Others

By End-User- Hospitals, Specialty Clinics and Other

By Distribution Channel- Hospital Pharmacy, Retail Pharmacy, Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029. For the purpose of this study, has segmented the Polycystic Kidney Disease Market report based on purity level, application, and region.

Polycystic Kidney Disease Market Segmentation

Polycystic Kidney Disease Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global Polycystic Kidney Disease Market Key Players

The major players covered in the polycystic kidney disease market are Taro Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis AG, Merck & Co. Inc., and Sanofi among others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.

Global Polycystic Kidney Disease Market Company Profile

  • Taro Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Otsuka Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG, Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sanofi
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Global Polycystic Kidney Disease Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for Polycystic Kidney Disease Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By Route of Administration
      • Market Snippet, By End-User
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Type, 2020 – 2030, (US$ Mn)
    • Overview                           
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Autosomal Dominant Polycystic Kidney Ease
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Autosomal Reccessive Polycystic Kidney Disease
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Market Segmentation, By Treatment, 2020 – 2030, (US$ Mn)
    • Overview                   
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Surgery
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Medication
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Market Segmentation, By Route of Administration, 2020 – 2030, (US$ Mn)
    • Overview                          
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Parenteral
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Market Segmentation, By End-User, 2020 – 2030, (US$ Mn)
    • Overview                          
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Specialty Stores
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  9. Market Segmentation, By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview            
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  10. Global Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  11. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  12. Company Profiles
  • Taro Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Otsuka Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG, Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sanofi
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

Polycystic Kidney Disease Market is segmented based on type, treatment, route of administration, end-users, distribution channel, and Region.

Growing case of kidney failure which is the major factor driving growth of the global market

North America has the greatest market share in terms of geographical estimation, owing to high healthcare expenditure and research and development.

The major players covered in the polycystic kidney disease market are Taro Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis AG, Merck & Co. Inc., and Sanofi among others